<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Clin. Infect. Dis</journal-id><journal-id journal-id-type="publisher-id">cid</journal-id><journal-title-group><journal-title>Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America</journal-title></journal-title-group><issn pub-type="ppub">1058-4838</issn><issn pub-type="epub">1537-6591</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7454384</article-id><article-id pub-id-type="pmid">32687168</article-id><article-id pub-id-type="doi">10.1093/cid/ciaa1028</article-id><article-id pub-id-type="publisher-id">ciaa1028</article-id><article-categories><subj-group subj-group-type="heading"><subject>Major Article</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00290</subject></subj-group></article-categories><title-group><article-title>Pan-Family Assays for Rapid Viral Screening: Reducing Delays in Public Health Responses During Pandemics</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Erlichster</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="AF0001">1</xref><xref ref-type="corresp" rid="c1"/><!--<email>erlichster@mx3diagnostics.com</email>--></contrib><contrib contrib-type="author"><name><surname>Chana</surname><given-names>Gursharan</given-names></name><xref ref-type="aff" rid="AF0001">1</xref><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Zantomio</surname><given-names>Daniela</given-names></name><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Goudey</surname><given-names>Benjamin</given-names></name><xref ref-type="aff" rid="AF0004">4</xref><xref ref-type="aff" rid="AF0005">5</xref></contrib><contrib contrib-type="author"><name><surname>Skafidas</surname><given-names>Efstratios</given-names></name><xref ref-type="aff" rid="AF0001">1</xref><xref ref-type="aff" rid="AF0006">6</xref></contrib></contrib-group><aff id="AF0001"><label>1</label>
<institution>MX3 Diagnostics,</institution> Melbourne, Victoria, <country country="AU">Australia</country></aff><aff id="AF0002"><label>2</label>
<institution>Department of Medicine, Royal Melbourne Hospital, University of Melbourne,</institution> Melbourne, Victoria, <country country="AU">Australia</country></aff><aff id="AF0003"><label>3</label>
<institution>Department of Haematology, Austin Health, Heidelberg,</institution> Victoria, <country country="AU">Australia</country></aff><aff id="AF0004"><label>4</label>
<institution>IBM Research Australia, Southbank, </institution>Victoria, <country country="AU">Australia</country></aff><aff id="AF0005"><label>5</label>
<institution>Centre for Epidemiology and Biostatistics, The University of Melbourne,</institution> Melbourne, Victoria, <country country="AU">Australia</country></aff><aff id="AF0006"><label>6</label>
<institution>Department of Electrical and Electronic Engineering, Melbourne School of Engineering, The University of Melbourne,</institution> Melbourne, Victoria, <country country="AU">Australia</country></aff><author-notes><corresp id="c1"><bold>Corresponding Author</bold><bold> Details:</bold> Michael Erlichster, 43/255 Drummond Street, Carlton. Victoria, Australia. Phone: +614 3803 4465. Email: <email>erlichster@mx3diagnostics.com</email></corresp></author-notes><pub-date pub-type="epub" iso-8601-date="2020-07-20"><day>20</day><month>7</month><year>2020</year></pub-date><elocation-id>ciaa1028</elocation-id><history><date date-type="received"><day>29</day><month>5</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.</copyright-statement><copyright-year>2020</copyright-year><license license-type="publisher-standard" xlink:href="https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model"><license-p>This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (<ext-link ext-link-type="uri" xlink:href="https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model">https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model</ext-link>)</license-p></license><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.</license-p></license></permissions><self-uri xlink:href="ciaa1028.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>COVID-19 has highlighted deficiencies in the testing capacity of many developed countries during the early stages of pandemics. Here we describe a strategy utilizing pan-family viral assays to improve early accessibility of large-scale nucleic acid testing.</p></sec><sec id="s2"><title>Methods</title><p>Coronaviruses and SARS-CoV-2 were used as a case-study for assessing utility of pan-family viral assays during the early stages of a novel pandemic. Specificity of a pan-coronavirus (Pan-CoV) assay for a novel pathogen was assessed using the frequency of common human coronavirus (HCoV) species in key populations. A reported Pan-CoV assay was assessed to determine sensitivity to 60 reference coronaviruses, including SARS-CoV-2. The resilience of the primer target regions of this assay to mutation was assessed in 8893 high-quality SARS-CoV-2 genomes to predict ongoing utility during pandemic progression.</p></sec><sec id="s3"><title>Results</title><p>Due to common HCoV species, a Pan-CoV assay would return false positives for as few as 1% of asymptomatic adults, but up to 30% of immunocompromised patients with respiratory disease. Half of reported Pan-CoV assays identify SARS-CoV-2 and with small adjustments can accommodate diverse variation observed in animal coronaviruses. The target region of one well established Pan-CoV assay is highly resistant to mutation compared to species-specific SARS-CoV-2 RT-PCR assays.</p></sec><sec id="s4"><title>Conclusions</title><p>Despite cross-reactivity with common pathogens, pan-family assays may greatly assist management of emerging pandemics through prioritization of high-resolution testing or isolation measures. Targeting highly conserved genomic regions make pan-family assays robust and resilient to mutation. A strategic stockpile of pan-family assays may improve containment of novel diseases prior to the availability of species-specific assays.</p></sec></abstract><kwd-group><kwd>Viral Screening</kwd><kwd>Pan-Family Assays</kwd><kwd>SARS-CoV-2</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>article-lifecycle</meta-name><meta-value>PAP</meta-value></custom-meta><custom-meta><meta-name>edited-state</meta-name><meta-value>accepted-manuscript</meta-value></custom-meta></custom-meta-group></article-meta></front></article>